The outbreak of the Omicron variant has raised many questions against the medical system. New York City is under a state of Emergency and the shortage of medical supplies and beds has become a common scenario in many states in the USA. The reducing effectiveness of vaccination amongst the major population has also raised the eyebrows of the Medical agencies in the country.
The US FDA Consultants Support Merck’s COVID Antiviral Medication.
The country is demanding something very strong that can help in the prevention of both delta and Omicron variants of Covid 19. It has been argued by many top-ranked medical professionals that the antiviral pills could have been a real game-changer for controlling COVID-19 and assisting people in recovering from the virus’s beginning stages. “With omicron [variations] breathing down our throat, we require prescription medications, really beneficial antivirals, and more of them.
As per Merck’s analysis of data, starting molnupiravir within 5 days of initial diagnosis lowers the risk of hospitalization and death in COVID-19 patient populations by 50% and these results are very promising.
As per some medical experts In order to decrease hospital admissions and deaths, the consequences for this Merck’s antiviral pill are also still substantial.
Although against Merck, Pfizer also presented its antiviral pill, Paxlovid, and has asked the FDA to authorize it as an emergency usage last week.
An advisory panel of the US Food and Drug Administration authorized the use of Merck’s antiviral pills for the treatment against the delta variant and new variant of coronavirus.
The members who voted in favor were 13 which is 3 more than the members who voted against the use of Antiviral pills. Since the favor ratio was high, it got authorization from the FDA Committee to start the use of Merck antiviral pills to reduce the hospitalization and death rates.
These antiviral drugs alter the sequence of the amino acids that form the proteins, causing the proteins to be deficient — and the newly constructed bacterial infection to be destroyed, unable to afflict new cells or recreate itself.
Also, Pfizer decided to apply to the US Administration (FDA on Tuesday for permission of its Paxlovid pill, which is intended to treat Covid patients and has shown an 89 percent reduction in the hospitalization and death rates. Steadily for the past month, Merck requested urgent approval from the FDA for its Covid drug, known as molnupiravir.
People take eight pills per day for 5 days, which may seem excessive, but Merck’s latest drug study is promising. Unimmunized patients with relatively mild Covid who obtained molnupiravir within 5 days of witnessing signs had a 50% decline in hospitalization and mortality rate. In this way, the hospitals will be able to manage the shortage of general beds and ICU beds for severe condition patients.
The US food and drug administration has not yet recommended that pregnant Americans consider taking Merck’s antiviral citing concerns raised in Merck’s animal experimentation of molnupiravir that it could hinder the child’s upbringing. Kids would also be barred from receiving the drugs.
